Developing next generation treatments to preserve vision for patients with diseases affecting the back of the eye

Oxurion NV Announces Initiation of Equity Analyst Coverage by H.C. Wainwright with a “Buy” Recommendation

4 Nov 2021

Leuven, BE, Boston, MA, US – November 4, 2021 – 07.00 AM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with a clinical stage portfolio in vascular retinal disorders, announces that H.C. Wainwright has initiated analyst coverage. 

H.C. Wainwright initiated coverage of Oxurion NV with a “Buy” rating and a price target of €5. H.C. Wainwright joins Roth Capital as the second US bank covering Oxurion. 

The H.C. Wainwright coverage initiation follows Oxurion achieving two important recent corporate milestones: 

  • Announcing topline positive data from Part A of the Company’s Phase 2 study of THR-149, a plasma kallikrein inhibitor, for the treatment of patients with Diabetic Macular Edema (DME) who respond suboptimally to anti-VEGF therapy 
  • The start of the Phase 2 clinical study evaluating THR-687, a pan RGD integrin antagonist, in patients with DME. 

All reports on Oxurion prepared by analysts represent the views of those analysts and are not necessarily those of Oxurion. Oxurion is not responsible for the content, accuracy, or timelines provided by analysts.

A copy of the full analysts’ note can be obtained directly from the banks.

By referring to these analysts or distributing their opinions, Oxurion does not in any way commit itself to the validity of such information, conclusions or recommendations.

Press release attachment: 
Tags: 
Company; THR-149; THR-687